MAPT and Alzheimer disease: One relevant study by Palmqvist et al. [38] demonstrated that a combination of baseline plasma (p-tau and NfL), MRI-based structural measures, and cognition was predictive of future progression to AD in individuals with subjective cognitive decline and MCI patients.